The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

Type 1 diabetes mellitus results from a T-cell mediated autoimmune destruction of the pancreatic beta cells in genetically predisposed individuals. The knowledge of the immunopathogenesis has increased enormously in the last two decades. The contribution of T-cells in the pathogenesis is beyond doubt. Therapies directed against T-cells have been shown to halt the disease process and prevent recurrent beta-cell destruction after islet transplantation. Less is known about the nature and function of these T-cells, the cause of the loss of tolerance to islet autoantigens, why the immune system apparently fails to suppress autoreactivity, and whether (or which) autoantigen(s) are critically involved in the initiation or progression of the disease. The contribution of dendritic cells in directing the immune response is clear, while the contribution of B-cells and autoantibodies is subject to reconsideration. Autoreactive T-cells have proven to be valuable tools to study pathogenic or diabetes-related processes. Measuring T-cell autoreactivity has also provided critical information to determine the fate of islet allografts transplanted to Type 1 diabetic patients. Cellular autoimmunity is a difficult study subject, but it has been a worthwhile quest to unravel the role of T-cells in the pathogenesis of Type 1 diabetes. The challenge for the future is to determine which factors contribute to the loss of tolerance to beta-cell antigens, and to define what measures T-cells can provide to suppress autoreactivity, since it is becoming increasingly evident that T-cells provide a two-edged sword: some T-cells could be pathogenic, but others can regulate the disease process and thus form new targets for immunointervention.

[1]  Andrew W. Liu,et al.  Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. , 2002, Diabetes.

[2]  G. Eisenbarth,et al.  T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects , 1997, Diabetologia.

[3]  G. Bruining.  Association between infant growth before onset of juvenile type-1 diabetes and autoantibodies to IA-2 , 2000, The Lancet.

[4]  S. Martin,et al.  Th1-like cytokine production profile and individual specific alterations in TCRBV-gene usage of T cells from newly diagnosed type 1 diabetes patients after stimulation with beta-cell antigens. , 1997, Journal of autoimmunity.

[5]  J. Rygaard,et al.  Dependence of Antigen Expression on Functional State of β-Cells , 1990, Diabetes.

[6]  E. Shevach,et al.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.

[7]  L. Chatenoud.  Restoration of self-tolerance is a feasible approach to control ongoing beta-cell specific autoreactivity: its relevance for treatment in established diabetes and islet transplantation , 2001, Diabetologia.

[8]  E. Thorsby,et al.  Molecular basis and functional importance of some disease-associated HLA polymorphisms. , 1989, Tissue antigens.

[9]  A. Geluk,et al.  Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes. , 1998, Journal of autoimmunity.

[10]  A. Chaudhuri,et al.  GAD65-Reactive T cells in a non-diabetic stiff-man syndrome patient. , 1999, Journal of autoimmunity.

[11]  G. Spinas,et al.  Lack of Predictive Value of Islet Cell Antibodies, Insulin Antibodies, and HLA-DR Phenotype for Remission in Cyclosporin-Treated IDDM Patients , 1990, Diabetes.

[12]  A. Chaudhuri,et al.  Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Bingley,et al.  Early T-cell defects in pre-type 1 diabetes , 2004, Acta Diabetologica.

[14]  J. Palmer,et al.  Insulin antibodies in insulin-dependent diabetics before insulin treatment. , 1983, Science.

[15]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[16]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[17]  C. Greenbaum,et al.  Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. , 1996, Journal of immunology.

[18]  P. Lehmann,et al.  T cell cross-reactivity between coxsackievirus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele , 1994, The Journal of experimental medicine.

[19]  H. Chase,et al.  Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects , 1997, Diabetologia.

[20]  J. Drijfhout,et al.  Antigen arrays in T cell immunology. , 2000, Current opinion in immunology.

[21]  J. Galama,et al.  Acute onset of type I diabetes mellitus after severe echovirus 9 infection: putative pathogenic pathways. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  H. Weiner,et al.  Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis , 1994, The Journal of experimental medicine.

[23]  J. Drijfhout,et al.  T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. , 2000, Diabetes.

[24]  E. Bonifacio,et al.  Autoantibody response to islet transplantation in type 1 diabetes. , 2001, Diabetes.

[25]  D. Harlan,et al.  Islet-infiltrating t lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2). , 1996, Journal of autoimmunity.

[26]  D. Vergani,et al.  Immunological studies on type 1 diabetes in identical twins. , 1993, Archives of disease in childhood.

[27]  Å. Lernmark,et al.  Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. , 1983, British medical journal.

[28]  F. Pociot,et al.  T cell proliferative responses to glutamic acid decarboxylase-65 in IDDM are negatively associated with HLA DR3/4. , 1995, Autoimmunity.

[29]  B. Roep,et al.  HLA class II associations with Type 1 diabetes mellitus: a multivariate approach. , 2001, Tissue antigens.

[30]  A. Tomlinson,et al.  Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. , 1999, The Journal of clinical investigation.

[31]  P. Bingley,et al.  Proposed guidelines on screening for risk of type 1 diabetes. , 2001, Diabetes care.

[32]  B. Roep.  T-Cell Responses to Autoantigens in IDDM: The Search for the Holy Grail , 1996, Diabetes.

[33]  D. R. Gamble,et al.  In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. , 1985, The New England journal of medicine.

[34]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[35]  Elina Hyppönen,et al.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.

[36]  J. Tuomilehto,et al.  Seasonality of birth in patients with type 1 diabetes , 2002, The Lancet.

[37]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[38]  L. Harrison,et al.  Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes , 1993, The Lancet.

[39]  F. Schuit,et al.  Genetic structure of IDDM1: two separate regions in the major histocompatibility complex contribute to susceptibility or protection. Belgian Diabetes Registry. , 1998, Diabetes.

[40]  M. Hussain,et al.  Increased Expression of T-Cell Markers of Immunological Memory Associated with Protection from Type I Diabetes: A study of Identical Twins , 1994, Diabetes.

[41]  G. Eisenbarth,et al.  Isohormonal therapy of endocrine autoimmunity. , 1995, Immunology today.

[42]  G. Hitman,et al.  Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. , 2002, Diabetes.

[43]  P. H. Moghaddam,et al.  Genetic Structure of IDDM1: Two Separate Regions in the Major Histocompatibility Complex Contribute to Susceptibility or Protection , 1998, Diabetes.

[44]  S. Martin,et al.  Development of type 1 diabetes despite severe hereditary B-cell deficiency. , 2001, The New England journal of medicine.

[45]  R. Coffman,et al.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. , 1994, Immunity.

[46]  M. Peakman,et al.  Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. , 2003, Diabetes.

[47]  Camillo Ricordi,et al.  The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes , 1997, Nature Genetics.

[48]  J. Drijfhout,et al.  Quantitative determination of TCR cross‐reactivity using peptide libraries and protein databases , 1999, European journal of immunology.

[49]  D. Hafler,et al.  Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes , 1998, Nature.

[50]  H. Kolb,et al.  Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation , 1993, The Lancet.

[51]  C. Boitard,et al.  Limited Duration of Remission of Insulin Dependency in Children With Recent Overt Type I Diabetes Treated With Low-Dose Cyclosporin , 1990, Diabetes.

[52]  M. Erlander,et al.  Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes , 1992, The Lancet.

[53]  Ji-Woon Yoon,et al.  ASSOCIATION OF CYTOMEGALOVIRUS INFECTION WITH AUTOIMMUNE TYPE 1 DIABETES , 1988, The Lancet.

[54]  L. Harrison,et al.  Islet-reactive T cells are a marker of preclinical insulin-dependent diabetes. , 1992, The Journal of clinical investigation.

[55]  L. Harrison,et al.  Glutamic acid decarboxylase 67-reactive T cells: a marker of insulin- dependent diabetes , 1993, The Journal of experimental medicine.

[56]  Troy Krahl,et al.  Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry , 1998, Nature Medicine.

[57]  Å. Lernmark,et al.  GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. , 2000, Diabetes.

[58]  C. Beaufort.  The EURODIAB Substudy 2 Study Group Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus , 1999 .

[59]  M. Mihatsch,et al.  Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.

[60]  I. Cohen,et al.  β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial , 2001, The Lancet.

[61]  D. Doniach,et al.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. , 1974, Lancet.

[62]  M. A. Bowman,et al.  Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. , 1994, The Journal of clinical investigation.

[63]  G. Eisenbarth,et al.  Abnormal T-Lymphocyte Subsets in Type I Diabetes , 1989, Diabetes.

[64]  J. Drijfhout,et al.  HLA-DR binding analysis of peptides from islet antigens in IDDM. , 1998, Diabetes.

[65]  G. Eisenbarth,et al.  Insulin prophylaxis in individuals at high risk of type 1 diabetes , 1993, The Lancet.

[66]  M. Atkinson,et al.  The NOD mouse model of type 1 diabetes: As good as it gets? , 1999, Nature Medicine.

[67]  Clare Baecher-Allan,et al.  Inhibition of Human CD4+CD25+high Regulatory T Cell Function1 , 2002, The Journal of Immunology.

[68]  Å. Lernmark,et al.  Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. , 1999, Diabetes.

[69]  H. Kolb,et al.  HLA‐associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent‐onset insulin‐dependent diabetes mellitus , 1996, European journal of immunology.

[70]  K. Yamagata,et al.  Examination of islets in the pancreas biopsy specimens from newly diagnosed Type 1 (insulin-dependent) diabetic patients , 1990, Diabetologia.

[71]  J. She,et al.  The relationship between humoral and cellular immunity to IA-2 in IDDM. , 1998, Diabetes.

[72]  M. Roncarolo,et al.  The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells , 2002, International Archives of Allergy and Immunology.

[73]  S. Arden,et al.  T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes , 1991, The Lancet.

[74]  S. Martin,et al.  Modulation of autoimmunity to beta-cell antigens by proteases , 2002, Diabetologia.

[75]  Å. Lernmark,et al.  Tolerance to kidney allograft transplanted into Type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches , 1999, Diabetologia.

[76]  M. Peakman,et al.  T-Cell markers in Type I diabetes: progress, prospects and realistic expectations , 2000, Diabetologia.

[77]  C. Mathieu,et al.  Seasonality of birth in patients with type 1 diabetes , 2002, The Lancet.

[78]  S. Arden,et al.  T-Cell Reactivity to β-Cell Membrane Antigens Associated With β-Cell Destruction in IDDM , 1995, Diabetes.

[79]  A. Gaur,et al.  A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. , 2001, The Journal of clinical investigation.

[80]  S. Arden,et al.  T-cell epitope analysis using subtracted expression libraries (TEASEL): application to a 38-kDA autoantigen recognized by T cells from an insulin-dependent diabetic patient. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[81]  C. Cha,et al.  Human pancreatic islet cell specific 38 kilodalton autoantigen identified by cytomegalovirus-induced monoclonal islet cell autoantibody , 1990, Diabetologia.

[82]  E. Gale.  Can we change the course of beta-cell destruction in type 1 diabetes? , 2002, The New England journal of medicine.

[83]  H. Mcdevitt.  Closing in on type 1 diabetes. , 2001, New England Journal of Medicine.

[84]  S. Martin,et al.  Circulating forms of ICAM-3 (cICAM-3). Elevated levels in autoimmune diseases and lack of association with cICAM-1. , 1995, Journal of immunology.

[85]  Roep Bo.  Standardization of T-cell assays in Type I diabetes. Immunology of Diabetes Society T-cell Committee. , 1999 .

[86]  D. Faustman.  Occult CD45 T cell developmental defect in type 1 diabetes. , 1993, Diabete & metabolisme.

[87]  C. Mathieu,et al.  Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). , 2002, Diabetes.

[88]  A. Ariza,et al.  Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. , 1994, Journal of immunology.

[89]  S. Arden,et al.  Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient. , 1996, The Journal of clinical investigation.

[90]  B. Koeleman,et al.  Seasonality of birth in patients with type 1 diabetes , 2002, The Lancet.

[91]  D. Wegmann,et al.  Epitope specificity, cytokine production profile and diabetogenic activity of insulin‐specific T cell clones isolated from NOD mice , 1995, European journal of immunology.

[92]  S. Martin,et al.  Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus , 1994, The Lancet.

[93]  Bart O. Roep,et al.  T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins , 1990, Nature.

[94]  D. Vergani,et al.  Co-expression of CD45RA (naive) and CD45RO (memory) T-cell markers , 1994, The Lancet.

[95]  I. Durinovic-Bello.  Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. , 1998, Autoimmunity.

[96]  E. Bonifacio,et al.  International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. , 2001, Diabetes.

[97]  W. Gepts.  Pathologic Anatomy of the Pancreas in Juvenile Diabetes Mellitus , 1965, Diabetes.

[98]  J. Leunissen,et al.  Definition of natural T cell antigens with mimicry epitopes obtained from dedicated synthetic peptide libraries. , 1998, Journal of immunology.

[99]  A. Michael,et al.  Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[100]  L. Chatenoud,et al.  CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. , 1997, Journal of immunology.

[101]  H. Kolb,et al.  Autoimmune versus inflammatory type I diabetes: a controversy? , 1995, Immunology today.

[102]  P. van Endert,et al.  Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays. , 1999, Journal of autoimmunity.

[103]  J. Phillips,et al.  Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. , 1999, Transplantation.

[104]  C Benoist,et al.  T helper cell subsets in insulin-dependent diabetes. , 1995, Science.

[105]  B. Roep,et al.  Autoreactive and immunoregulatory T-cell subsets in insulindependent diabetes mellitus , 1999, Diabetologia.

[106]  R. Nakhleh,et al.  Characterization of T Lymphocytes Infiltrating Human Pancreas Allograft Affected by Isletitis and Recurrent Diabetes , 1992, Diabetes.

[107]  P. Pozzilli,et al.  Persistent reduction of CD4/CD8 lymphocyte ratio amd cell activation before the onset of Type 1 (insulin-dependent) diabetes , 1989, Diabetologia.

[108]  H Atlan,et al.  T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. , 1999, Journal of autoimmunity.

[109]  M. Knip,et al.  Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. , 1996, The Journal of clinical investigation.

[110]  M. Oldstone.  Molecular mimicry and immune‐mediated diseases , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  R. V. van Lier,et al.  Increased numbers of in vivo activated T cells in patients with recent onset insulin-dependent diabetes mellitus. , 1996, Journal of autoimmunity.

[112]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[113]  H. Drexhage,et al.  Defective maturation and function of antigen-presenting cells in type 1 diabetes , 1995, The Lancet.

[114]  J. Drijfhout,et al.  Molecular mimicry in type 1 diabetes mellitus revisited: T-cell clones to GAD65 peptides with sequence homology to Coxsackie or proinsulin peptides do not crossreact with homologous counterpart. , 2001, Human immunology.

[115]  S. Johnson,et al.  Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[116]  B. Roep,et al.  Inhibition of insulin-specific autoreactive T-cells by sulphatide which is variably expressed in beta cells , 1999, Diabetologia.